Imipenem/cilastatin/relebactam treatment of hospital-acquired/ventilator-associated bacterial pneumonia caused by imipenem-nonsusceptible pathogens: Subgroup analysis and molecular characterization of isolates from the RESTORE-IMI 2 clinical study

Katherine Young, C Andrew DeRyke, David W Hilbert, Maria C Losada, Jiejun Du, Amanda Paschke, Luke F Chen · 2026

Read Imipenem/cilastatin/relebactam treatment of hospital-acquired/ventilator-associated bacterial pneumonia caused by imipenem-nonsusceptible pathogens: Subgroup analysis and molecular characterization of isolates from the RESTORE-IMI 2 clinical study by Katherine Young, C Andrew DeRyke, David W Hilbert, Maria C Losada, Jiejun Du, Amanda Paschke, Luke F Chen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0357288.txt.

Description

Katherine Young is first author on a 2026 PLOS ONE subgroup analysis of a trial in severe lung infection caught during hospital care. Such infections increasingly involve germs that resist carbapenems, a last-line drug class, leaving few options. The study drug adds relebactam to imipenem to shield it from bacterial enzymes.

Within the RESTORE-IMI 2 trial, the authors compared patients whose lung germs resisted imipenem but stayed sensitive to the pairing against those with sensitive germs. Death rates by day twenty-eight were similar in the two groups. New resistance to the pairing emerged during treatment in only three patients. Lab checks described the resistant isolates in detail.

Catalog record

CREATORKatherine Young, C Andrew DeRyke, David W Hilbert, Maria C Losada, Jiejun Du, Amanda Paschke, Luke F Chen
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE30043
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0357288

Browse the full library · About the Tower of Babel